Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.02B | 1.00B | 1.10B | 1.07B | 1.37B |
| Total Depreciation and Amortization | 171.20M | 165.50M | 160.90M | 156.60M | 156.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 605.40M | 478.70M | 308.20M | 210.50M | 55.10M |
| Change in Net Operating Assets | -81.00M | 71.20M | -206.70M | 154.60M | -562.80M |
| Cash from Operations | 1.72B | 1.72B | 1.36B | 1.60B | 1.02B |
| Capital Expenditure | -292.80M | -286.70M | -269.10M | -260.20M | -212.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -33.70M | -33.70M | -35.10M | -- | -298.20M |
| Divestitures | 42.50M | 42.50M | 42.50M | 42.50M | 3.93B |
| Other Investing Activities | -456.70M | -634.20M | -629.30M | -495.20M | -4.51B |
| Cash from Investing | -740.70M | -912.10M | -891.00M | -712.90M | -1.09B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 191.50M | 189.70M | 193.10M | 174.10M | 170.40M |
| Repurchase of Common Stock | -754.60M | -1.15B | -1.11B | -893.40M | -852.90M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -600.00K | -238.30M | -236.50M | -237.50M | -234.30M |
| Cash from Financing | -563.70M | -1.20B | -1.15B | -956.80M | -916.80M |
| Foreign Exchange rate Adjustments | 5.10M | 14.50M | -18.90M | -44.80M | 2.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 417.60M | -380.30M | -701.30M | -119.30M | -988.60M |